Hyderabad India – May 30th 2018
Granules Pharmaceuticals, Inc., the wholly owned
subsidiary of Granules India Ltd., has launched the generic version of Methylergonovine
Maleate Tablets, USP, 0.2mg, the generic equivalent to Methergine in partnership with WestWard
Pharmaceuticals Corp. (West-Ward), a wholly-owned subsidiary of Hikma
Pharmaceuticals PLC (Hikma).
Methylergonovine is a semi-synthetic ergot alkaloid used for the prevention and control
of postpartum haemorrhage.
“This is the first product we have commercialized from our R&D and manufacturing facility in
Virginia and we are happy to have collaborated with Hikma . Apart from the fact that Hikma
has a proven history of being a responsible player in the market, we look at this launch as the
inception towards building a strategic relationship. The launch of generic Methergine tablets
plays into our strategy of identifying patient needs and catering to them with economical
alternatives.” said Ms. Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals,
Inc.
Brian Hoffmann, President of West-Ward, said, “We are very pleased to be entering into a
partnership with Granules Pharmaceuticals, Inc., adding this important oxytocic agent to our
product portfolio in the US. This partnership demonstrates our focus on improving patient’s
access to high-quality, affordable medicines.”
About Granules India Ltd. (BSE: 532482, NSE: GRANULES)
Granules India is a growing pharmaceutical manufacturing company with best in class facilities and is
committed to operational excellence, quality and customer service. The Company produces Finished
Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients
(APIs) which gives the customers flexibility and choice. Granules India support customers with unique
value, extensive product range, and proactive solutions. The Company’s global presence extends to over
250 customers in 60 countries through offices in India, U.S., and U.K.
About Hikma
Hikma helps put better health within reach every day for millions of people in more than 50 countries
around the world. For 40 years, we’ve been creating high-quality medicines and making them accessible to
the people who need them. We’re a global company with a local presence across the United States (US),
the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to
transform cutting-edge science into innovative solutions that transform people’s lives. We’re committed to
our customers, and the people they care for, and by thinking creatively and acting practically, we provide
them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues
are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner
in the MENA region, and through our venture capital arm, are helping bring innovative health technologies
to people around the world. For more information, please visit www.hikma.com.
Contacts:
Sumanta Bajpayee
Corporate Finance & Investor Relations
040-30663572
sumanta.bajpayee@granulesindia.com
